Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.
- In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.
- Of these potential future payments, Ovid sold a 13% interest to Ligand Pharmaceuticals for $30 million in October 2023.
- Financial runway: Ovid anticipates its cash runway will support operations and clinical development programs into the first half of 2026.
- Ovid also anticipates several events for its current pipeline programs and clinical results for soticlestat from Takeda in 2024.